{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:40:55Z","timestamp":1793911255503,"version":"4.8.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:00:00Z","timestamp":1759017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:00:00Z","timestamp":1759017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01-AG065253"],"award-info":[{"award-number":["R01-AG065253"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40265-025-02250-5","type":"journal-article","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:53:13Z","timestamp":1759067593000},"page":"1455-1472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOE\u03b54\/\u03b54 Homozygotes with Early Alzheimer\u2019s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial"],"prefix":"10.1007","volume":"85","author":[{"given":"Susan","family":"Abushakra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Porsteinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emer","family":"MacSweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Murali","family":"Doraiswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earvin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Patrick","family":"Kesslak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"McLaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"Albayrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Hey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,28]]},"reference":[{"key":"2250_CR1","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","volume":"20","author":"Alzheimer\u2019s Association 2024","year":"2024","unstructured":"Alzheimer\u2019s Association 2024. Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement. 2024;20:3708\u2013821. https:\/\/doi.org\/10.1002\/alz.13809.","journal-title":"Alzheimer\u2019s Dement."},{"issue":"2","key":"2250_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson A, Norton N, Fast T, et al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement. 2023;19(2):658\u201370.","journal-title":"Alzheimers Dement"},{"key":"2250_CR3","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association workgroup. Alzheimers Dement. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"key":"2250_CR4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw BJ, Betensky RA, Jacobs H, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76:915\u201324. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1424.","journal-title":"JAMA Neurol"},{"key":"2250_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101911","volume":"87","author":"Y Chen","year":"2023","unstructured":"Chen Y, Wang Y, Song Z, et al. Abnormal white matter changes in Alzheimer\u2019s disease based on diffusion tensor imaging: a systematic review. Ageing Res Rev. 2023;87:101911.","journal-title":"Ageing Res Rev"},{"key":"2250_CR6","doi-asserted-by":"publisher","first-page":"9060","DOI":"10.1002\/alz.14306","volume":"20","author":"T Schaap","year":"2024","unstructured":"Schaap T, Thropp P, Tosun D, Alzheimer\u2019s Disease Neuroimaging Initiative. Timing of Alzheimer\u2019s disease biomarker progressions: a two-decade observational study from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2024;20:9060\u20137. https:\/\/doi.org\/10.1002\/alz.14306.","journal-title":"Alzheimers Dement"},{"key":"2250_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s43587-025-00810-8","volume":"5","author":"E Andersson","year":"2025","unstructured":"Andersson E, Lindblom N, Janelidze S, et al. Soluble cerebral A\u03b2 protofibrils link A\u03b2 plaque pathology to changes in CSF A\u03b242\/A\u03b240 ratios, neurofilament light and tau in Alzheimer\u2019s disease model mice. Nat Aging. 2025;5:366\u201375. https:\/\/doi.org\/10.1038\/s43587-025-00810-8.","journal-title":"Nat Aging"},{"key":"2250_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14415","volume":"21","author":"R Cacciaglia","year":"2025","unstructured":"Cacciaglia R, Falc\u00f3n C, Benavides GS, et al. Soluble A\u03b2 pathology predicts neurodegeneration and cognitive decline independently on p-tau in the earliest Alzheimer\u2019s continuum: evidence across two independent cohorts. Alzheimers Dement. 2025;21:e14415. https:\/\/doi.org\/10.1002\/alz.14415.","journal-title":"Alzheimers Dement"},{"key":"2250_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052727","volume":"25","author":"M Tolar","year":"2024","unstructured":"Tolar M, Hey JA, Power A, Abushakra S. The single toxin origin of Alzheimer\u2019s disease and other neurodegenerative disorders enables targeted approach to treatment and prevention. Int J Mol Sci. 2024;25:2727. https:\/\/doi.org\/10.3390\/ijms25052727.","journal-title":"Int J Mol Sci"},{"key":"2250_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00663-w","volume":"12","author":"M Tolar","year":"2020","unstructured":"Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801\u2013 the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval. Alzheimers Res Ther. 2020;12:95. https:\/\/doi.org\/10.1186\/s13195-020-00663-w.","journal-title":"Alzheimers Res Ther"},{"key":"2250_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126355","volume":"22","author":"M Tolar","year":"2021","unstructured":"Tolar M, Hey J, Power A, Abushakra S. Neurotoxic soluble amyloid oligomers drive Alzheimer\u2019s pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci. 2021;22:6355. https:\/\/doi.org\/10.3390\/ijms22126355.","journal-title":"Int J Mol Sci"},{"key":"2250_CR12","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1212\/wnl.43.8.1467","volume":"43","author":"AM Saunders","year":"1993","unstructured":"Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer\u2019s disease. Neurology. 1993;43:1467\u201372. https:\/\/doi.org\/10.1212\/wnl.43.8.1467.","journal-title":"Neurology"},{"key":"2250_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261:921\u20133. https:\/\/doi.org\/10.1126\/science.8346443.","journal-title":"Science"},{"key":"2250_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, et al. Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11:667. https:\/\/doi.org\/10.1038\/s41467-019-14279-8.","journal-title":"Nat Commun"},{"key":"2250_CR15","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1212\/01.wnl.0000188871.74093.12","volume":"65","author":"CA Martins","year":"2005","unstructured":"Martins CA, Oulhaj A, de Jager CA, et al. Apoe alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology. 2005;65:1888\u201393. https:\/\/doi.org\/10.1212\/01.wnl.0000188871.74093.12.","journal-title":"Neurology"},{"key":"2250_CR16","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924\u201338. https:\/\/doi.org\/10.1001\/jama.2015.4668.","journal-title":"JAMA"},{"issue":"5","key":"2250_CR17","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","volume":"30","author":"J Fortea","year":"2024","unstructured":"Fortea J, Pegueroles J, Alcolea D, et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer\u2019s disease. Nat Med. 2024;30(5):1284\u201391. https:\/\/doi.org\/10.1038\/s41591-024-02931-w.","journal-title":"Nat Med"},{"key":"2250_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.862369","volume":"13","author":"CG Withington","year":"2022","unstructured":"Withington CG, Turner RS. Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer\u2019s disease. Front Neurol. 2022;13:862369. https:\/\/doi.org\/10.3389\/fneur.2022.862369.","journal-title":"Front Neurol"},{"key":"2250_CR19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40265-024-02067-8","volume":"84","author":"JA Hey","year":"2024","unstructured":"Hey JA, Abushakra S, Blennow K, et al. Effects of oral ALZ-801\/valiltramiprosate on plasma biomarkers, brain hippocampal volume, and cognition: results of 2-year single-arm, open-label, phase 2 trial in APOE4 carriers with early Alzheimer\u2019s disease. Drugs. 2024;84:811\u201323. https:\/\/doi.org\/10.1007\/s40265-024-02067-8.","journal-title":"Drugs"},{"key":"2250_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40263-017-0434-z","volume":"31","author":"P Kocis","year":"2017","unstructured":"Kocis P, Tolar M, Yu J, et al. Elucidating the A\u03b242 anti-aggregation mechanism of action of tramiprosate in Alzheimer\u2019s disease: integrating molecular analytical methods, pharmacokinetic and clinical data. CNS Drugs. 2017;31:495\u2013509. https:\/\/doi.org\/10.1007\/s40263-017-0434-z.","journal-title":"CNS Drugs"},{"key":"2250_CR21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","volume":"32","author":"JA Hey","year":"2018","unstructured":"Hey JA, Kocis P, Hort J, et al. Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain. CNS Drugs. 2018;32:849\u201361. https:\/\/doi.org\/10.1007\/s40263-018-0554-0.","journal-title":"CNS Drugs"},{"key":"2250_CR22","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.1021\/acs.jctc.9b00599","volume":"15","author":"C Liang","year":"2019","unstructured":"Liang C, Savinov SN, Fejzo J, et al. Modulation of amyloid-\u03b242 conformation by small molecules through nonspecific binding. J Chem Theory Comput. 2019;15:5169\u201374. https:\/\/doi.org\/10.1021\/acs.jctc.9b00599.","journal-title":"J Chem Theory Comput"},{"key":"2250_CR23","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202402622R","volume":"39","author":"D Muramatsu","year":"2025","unstructured":"Muramatsu D, Watanabe-Nakayama T, Tsuji M, et al. ALZ-801 prevents amyloid \u03b2-protein assembly and reduces cytotoxicity: a preclinical experimental study. FASEB J. 2025;39:e70382. https:\/\/doi.org\/10.1096\/fj.202402622R.","journal-title":"FASEB J"},{"key":"2250_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5114\/aoms.2011.20612","volume":"7","author":"PS Aisen","year":"2011","unstructured":"Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in mild-to-moderate Alzheimer\u2019s disease\u2014a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase study). Arch Med Sci. 2011;7:102\u201311. https:\/\/doi.org\/10.5114\/aoms.2011.20612.","journal-title":"Arch Med Sci"},{"key":"2250_CR25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","volume":"13","author":"S Gauthier","year":"2009","unstructured":"Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer\u2019s disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging. 2009;13:550\u20137. https:\/\/doi.org\/10.1007\/s12603-009-0106-x.","journal-title":"J Nutr Health Aging"},{"issue":"2","key":"2250_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.psym.2015.12.002","volume":"57","author":"EK Degenhardt","year":"2016","unstructured":"Degenhardt EK, Witte MM, Case M, et al. Florbetapir F18 PET amyloid neuroimaging and characteristics in patients with mild and moderate Alzheimer dementia. Psychosomatics. 2016;57(2):208\u201316.","journal-title":"Psychosomatics"},{"key":"2250_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.14283\/jpad.2016.115","volume":"3","author":"S Abushakra","year":"2016","unstructured":"Abushakra S, Porsteinsson A, Vellas B, et al. Clinical benefits of tramiprosate in Alzheimer\u2019s disease are associated with higher number of APOE4 alleles: the \u201cAPOE4 gene-dose effect.\u201d J Prev Alzheimers Dis. 2016;3:219\u201328. https:\/\/doi.org\/10.14283\/jpad.2016.115.","journal-title":"J Prev Alzheimers Dis."},{"key":"2250_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14283\/jpad.2017.26","volume":"4","author":"S Abushakra","year":"2017","unstructured":"Abushakra S, Porsteinsson A, Scheltens P, et al. Clinical effects of tramiprosate in APOE4\/4 homozygous patients with mild Alzheimer\u2019s disease suggest disease modification potential. J Prev Alzheimers Dis. 2017;4:149\u201356. https:\/\/doi.org\/10.14283\/jpad.2017.26.","journal-title":"J Prev Alzheimers Dis"},{"key":"2250_CR29","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggans Evans C, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708.","journal-title":"N Engl J Med"},{"key":"2250_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L S\u00f6derberg","year":"2023","unstructured":"S\u00f6derberg L, Johannesson M, Nygren P, et al. Lecanemab, aducanumab, and gantenerumab\u2014binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease. Neurotherapeutics. 2023;20:195\u2013206. https:\/\/doi.org\/10.1007\/s13311-022-01308-6.","journal-title":"Neurotherapeutics"},{"key":"2250_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"2250_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"key":"2250_CR33","doi-asserted-by":"publisher","first-page":"e1265","DOI":"10.1212\/WNL.0000000000200892","volume":"99","author":"F Piazza","year":"2022","unstructured":"Piazza F, Caminiti SP, Zedde M, et al. Association of microglial activation with spontaneous ARIA-E and CSF levels of anti-A\u03b2 autoantibodies. Neurology. 2022;99:e1265\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000200892.","journal-title":"Neurology"},{"key":"2250_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, et al. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis. 2022;9:211\u201320. https:\/\/doi.org\/10.14283\/jpad.2022.21.","journal-title":"J Prev Alzheimers Dis"},{"key":"2250_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, Backsai BJ, Hernandez Guillamon M, et al. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol. 2020;16:30\u201342. https:\/\/doi.org\/10.1038\/s41582-019-0281-2.","journal-title":"Nat Rev Neurol"},{"key":"2250_CR36","doi-asserted-by":"publisher","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","volume":"100","author":"F Alves","year":"2023","unstructured":"Alves F, Kalinowski P, Ayton S. Accelerated brain volume loss caused by anti-\u03b2-amyloid drugs: a systematic review and meta-analysis. Neurology. 2023;100:e2114\u201324. https:\/\/doi.org\/10.1212\/WNL.0000000000207156.","journal-title":"Neurology"},{"key":"2250_CR37","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1474-4422(24)00335-1","volume":"23","author":"CRS Belder","year":"2024","unstructured":"Belder CRS, Boche D, Nicoll J, et al. Brain volume change following anti-amyloid \u03b2 immunotherapy for Alzheimer\u2019s disease: amyloid-removal-related pseudo-atrophy. Lancet Neurol. 2024;23:1025\u201334. https:\/\/doi.org\/10.1016\/S1474-4422(24)00335-1.","journal-title":"Lancet Neurol"},{"key":"2250_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.14283\/jpad.2023.92","volume":"11","author":"M Ten Kate","year":"2024","unstructured":"Ten Kate M, Barkhof F, Schwarz AJ. Consistency between treatment effects on clinical and brain atrophy outcomes in Alzheimer\u2019s disease trials. J Prev Alzheimers Dis. 2024;11:38\u201347. https:\/\/doi.org\/10.14283\/jpad.2023.92.","journal-title":"J Prev Alzheimers Dis"},{"key":"2250_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12498","volume":"10","author":"S Abushakra","year":"2024","unstructured":"Abushakra S, Porsteinsson A, Sabbagh M, et al. APOLLOE4 phase 3 study of oral ALZ-801\/valiltramiprosate in APOE\u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease: trial design & baseline characteristics. Alzheimers Dement (NY). 2024;10:e12498. https:\/\/doi.org\/10.1002\/trc2.12498.","journal-title":"Alzheimers Dement (NY)."},{"key":"2250_CR40","unstructured":"US Food and Drug Administration, Guidance Document. Early Alzheimer\u2019s disease: developing drug for treatment. 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/early-alzheimers-disease-developing-drugs-treatment. Accessed 01 Aug 2025."},{"issue":"S6","key":"2250_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/alz.066333","volume":"18","author":"SI Thomopoulos","year":"2022","unstructured":"Thomopoulos SI, Nir TM, Villalon Reina JE, et al. Effects of dementia and MCI on diffusion tensor metrics using the updated ADNI3 DTI preprocessing pipeline. Alzheimers Dement. 2022;18(S6):e066333. https:\/\/doi.org\/10.1002\/alz.066333.","journal-title":"Alzheimers Dement"},{"key":"2250_CR42","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1002\/alz.14166.022-01308-6","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Arani A, Borowski BJ, et al. Overview of ADNI MRI. Alzheimers Dement. 2024;20:7350\u201360. https:\/\/doi.org\/10.1002\/alz.14166.022-01308-6.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2250_CR43","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/sim.3495","volume":"28","author":"F Bretz","year":"2009","unstructured":"Bretz F, Maurer W, Brannath W, et al. A graphical approach to sequentially rejective multiple test procedures. Stat Med. 2009;28(4):586\u2013604.","journal-title":"Stat Med"},{"key":"2250_CR44","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:322\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1304839.","journal-title":"N Engl J Med"},{"key":"2250_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12117","volume":"6","author":"S Abushakra","year":"2020","unstructured":"Abushakra S, Porsteinsson A, Sabbagh M, et al. APOE \u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline. Alzheimer\u2019s Dementia. 2020;6:e12117. https:\/\/doi.org\/10.1002\/trc2.12117.","journal-title":"Alzheimer's Dementia"},{"key":"2250_CR46","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/brain\/awp007","volume":"132","author":"N Schuff","year":"2009","unstructured":"Schuff N, Woerner N, Boreta L, et al. MRI of hippocampal volume loss in early Alzheimer\u2019s disease in relation to ApoE genotype and biomarkers. Brain. 2009;132:1067\u201377. https:\/\/doi.org\/10.1093\/brain\/awp007.","journal-title":"Brain"},{"key":"2250_CR47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cortex.2014.04.006","volume":"57","author":"W Li","year":"2014","unstructured":"Li W, Antuono PG, Xie C, et al. Aberrant functional connectivity in Papez circuit correlates with memory performance in cognitively intact middle-aged APOE4 carriers. Cortex. 2014;57:167\u201376. https:\/\/doi.org\/10.1016\/j.cortex.2014.04.006.","journal-title":"Cortex"},{"key":"2250_CR48","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","volume":"28","author":"F Gervais","year":"2007","unstructured":"Gervais F, Paquette J, Morissette C, et al. Targeting soluble Abeta peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007;28:537\u201347. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2006.02.015.","journal-title":"Neurobiol Aging"},{"key":"2250_CR49","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000490349","volume":"65","author":"H Benveniste","year":"2019","unstructured":"Benveniste H, Liu X, Koundal S, Sanggaard S, et al. The glymphatic system and waste clearance with brain aging: a review. Gerontology. 2019;65:106\u201319. https:\/\/doi.org\/10.1159\/000490349.","journal-title":"Gerontology"},{"issue":"4","key":"2250_CR50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11(4):457\u201370. https:\/\/doi.org\/10.1038\/nrneurol.2015.119.","journal-title":"Nat Rev Neurol"},{"key":"2250_CR51","doi-asserted-by":"publisher","first-page":"7698","DOI":"10.1523\/JNEUROSCI.0619-21.2021","volume":"41","author":"LM Hablitz","year":"2021","unstructured":"Hablitz LM, Nedergaard M. The glymphatic system: a novel component of fundamental neurobiology. J Neurosci. 2021;41:7698\u2013711. https:\/\/doi.org\/10.1523\/JNEUROSCI.0619-21.2021.","journal-title":"J Neurosci"},{"key":"2250_CR52","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, Sperling R, Donohue MC. The AHEAD 3\u201345 study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:1227\u201333. https:\/\/doi.org\/10.1002\/alz.12748.","journal-title":"Alzheimers Dement"},{"key":"2250_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000334607","volume":"38","author":"A Ward","year":"2012","unstructured":"Ward A, Crean S, Mercaldi CJ, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4\/4) among patients diagnosed with Alzheimer\u2019s disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38:1\u201317. https:\/\/doi.org\/10.1159\/000334607.","journal-title":"Neuroepidemiology"},{"key":"2250_CR54","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1001\/jamaneurol.2023.3599","volume":"80","author":"ME Belloy","year":"2023","unstructured":"Belloy ME, Andrews SJ, Le Guen Y, et al. APOE genotype and Alzheimer disease risk across age, sex, and population ancestry. JAMA Neurol. 2023;80:1284\u201394. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3599.","journal-title":"JAMA Neurol"},{"key":"2250_CR55","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/mp.2011.52","volume":"16","author":"E Genin","year":"2011","unstructured":"Genin E, Hannequin D, Wallon D, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011;16:903\u20137. https:\/\/doi.org\/10.1038\/mp.2011.52.","journal-title":"Mol Psychiatry"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02250-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02250-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02250-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:31:21Z","timestamp":1761715881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02250-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,28]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2250"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02250-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,28]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alzheon employees receive salary compensation and stocks and\/or stock options from Alzheon Inc. The AD experts (A. Porsteinsson, M. Sabbagh, M. Doraiswamy) received consulting fees\u00a0and stocks or stock options from Alzheon Inc, and multiple other pharmaceutical companies developing CNS drugs, devices, or diagnostic tests. The site investigators (D. Watson, E. MacSweeney, S. Cohen, M. Boada-Rivera) received investigator fees for this study and multiple other AD and CNS trials from various global pharmaceutical companies. S. Dickinson is an employee of Pentara Inc., which provided statistical services and receives compensation from Alzheon Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The data that support the findings of this study are available from Alzheon, Inc., but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of Alzheon, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data"}},{"value":"The APOLLOE4 trial was approved by Adverra Central IRB and by the required local university IRBs in the US, and by country-specific ethics committees in the UK and EU. Alzheon certifies that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants signed written informed consent to participate in the trial before screening.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Alzheon employees: S. Abushakra is the principal investigator on the NIA grant for the APOLLOE4 trial. S. Abushakra, A. Power, E. Liang, S. Flint, J., L. Tolar, Hey and M. Tolar designed the trial and oversaw its conduct, data analysis, data interpretation, and manuscript preparation. All other Alzheon employees contributed to one or more of the following: trial conduct and oversight, safety oversight, and data analysis and interpretation. Advisors: A. Porsteinsson and M. Sabbagh were advisors for clinical trial design, data interpretation and manuscript preparation and\/or review. P.M. Doraiswamy was scientific advisor and provided manuscript reviews and critiques. D. Watson, E. McSweeney, S. Cohen, and M. Boada-Rivera were trial investigators in the United States, United Kingdom, Canada, and Europe, respectively; they contributed to the trial conduct, safety discussions, data interpretation and manuscript preparation. S. Dickson contributed to statistical methods and data analysis.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}